Visit | Mean | SD | Change from screen (%) | p Value | |
TGFβ1 expression by epithelial cells (score) | |||||
Mepolizumab (n = 5) | Screening | 2.50 | 0.97 | ||
Week 4 | 2.00 | 0.82 | −20 | NS | |
Week 13 | 1.70 | 0.67 | −32 | 0.0500 | |
Placebo (n = 6) | Screening | 2.50 | 0.79 | ||
Week 4 | 3.08 | 0.51 | +23 | NS | |
Week 13 | 3.00 | 0.43 | +20 | NS | |
Tenascin C expression in epithelial cell layer (score) | |||||
Mepolizumab (n = 5) | Screening | 3.00 | 1.05 | ||
Week 4 | 1.50 | 0.85 | −50 | 0.0057 | |
Week 13 | 1.40 | 0.52 | −53 | 0.0021 | |
Placebo (n = 6) | Screening | 1.67 | 1.07 | ||
Week 4 | 2.08 | 0.90 | +25 | n.s. | |
Week 13 | 2.33 | 0.89 | +40 | n.s. |
NS, non-significant; TGFβ1, transforming growth factor β1.